MGMT Pyrosequencing-Based Cut-Off Methylation Level and Clinical Outcome in Patients with Glioblastoma Multiforme

References

• Louis DN , OhgakiH, WiestlerODet al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol.114(2), 97–109 (2007).
   PubMed Web of Science ®Google Scholar
• Jhanwar-Uniyal M , LabagnaraM, FriedmanM, KwasnickiA, MuraliR. Glioblastoma: molecular pathways, stem cells and therapeutic targets. Cancers (Basel)7(2), 538–555 (2015).
   PubMed Web of Science ®Google Scholar
• Johnson DR , O’NeillBP. Glioblastoma survival in the United States before and during the temozolomide era. J. Neurooncol.107(2), 359–364 (2012).
   PubMed Web of Science ®Google Scholar
• Stupp R , MasonWP, van den BentMJet al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Pegg AE . Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res.50(19), 6119–6129 (1990).
   PubMed Web of Science ®Google Scholar
• Esteller M . CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene21(35), 5427–5440 (2002).
   PubMed Web of Science ®Google Scholar
• Hegi ME , LiuL, HermanJGet al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol.26(25), 4189–4199 (2008).
   PubMed Web of Science ®Google Scholar
• Gorlia T , van den BentMJ, HegiMEet al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol.9(1), 29–38 (2008).
   PubMed Web of Science ®Google Scholar
• Hegi ME , DiserensA-C, GorliaTet al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Hegi ME , DiserensA-C, GodardSet al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res.10(6), 1871–1874 (2004).
   PubMed Web of Science ®Google Scholar
• Esteller M , SilvaJM, DominguezGet al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst.92(7), 564–569 (2000).
   PubMedGoogle Scholar
• Brandes AA , FranceschiE, TosoniAet al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer115(15), 3512–3518 (2009).
   PubMed Web of Science ®Google Scholar
• Wick W , PlattenM, MeisnerCet al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, Phase 3 trial. Lancet Oncol.13(7), 707–715 (2012).
   PubMed Web of Science ®Google Scholar
• Malmström A , gr⊘nbergBH, MarosiCet al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, Phase 3 trial. Lancet Oncol.13(9), 916–926 (2012).
   PubMed Web of Science ®Google Scholar
• Karayan-Tapon L , QuillienV, GuilhotJet al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J. Neurooncol.97(3), 311–322 (2010).
   PubMed Web of Science ®Google Scholar
• Mikeska T , BockC, El-MaarriOet al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J. Mol. Diagnostics JMD9(3), 368–381 (2007).
   PubMed Web of Science ®Google Scholar
• Quillien V , LavenuA, Karayan-TaponLet al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g. Cancer118(17), 4201–4211 (2012).
   PubMed Web of Science ®Google Scholar
• Preusser M , BerghoffAS, ManzlCet al. Clinical neuropathology practice news 1–2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. Clin. Neuropathol.33(1), 6–14 (2014).
   PubMed Web of Science ®Google Scholar
• Weller M , StuppR, ReifenbergerGet al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 6(1), 39–51 (2010).
   PubMed Web of Science ®Google Scholar
• Dunn J , BaborieA, AlamFet al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br. J. Cancer101(1), 124–131 (2009).
   PubMed Web of Science ®Google Scholar
• Yan H , ParsonsDW, JinGet al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.360(8), 765–773 (2009).
   PubMed Web of Science ®Google Scholar
• Wick W , HartmannC, EngelCet al. NOA-04 randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol.27(35), 5874–5880 (2009).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ , DubbinkHJ, MarieYet al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res.16(5), 1597–1604 (2010).
   PubMed Web of Science ®Google Scholar
• Weller M , FelsbergJ, HartmannCet al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol.27(34), 5743–5750 (2009).
   PubMed Web of Science ®Google Scholar
• Sanson M , MarieY, ParisSet al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol.27(25), 4150–4154 (2009).
   PubMed Web of Science ®Google Scholar
• Zou P , XuH, ChenPet al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS ONE8(7), e68782 (2013).
   PubMed Web of Science ®Google Scholar
• De Maglio G , CasagrandeM, GuardascioneMet al. MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors. Future Oncol.11(8), 1201–1209 (2015).
   PubMed Web of Science ®Google Scholar
• Felsberg J , WolterM, SeulHet al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol.119(4), 501–507 (2010).
   PubMed Web of Science ®Google Scholar
• Gerson SL . MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer4(4), 296–307 (2004).
   PubMed Web of Science ®Google Scholar
• Hartmann C , HentschelB, SimonMet al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin. Cancer Res.19(18), 5146–5157 (2013).
   PubMed Web of Science ®Google Scholar
• Cheng H-B , YueW, XieC, ZhangR-Y, HuS-S, WangZ. IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis. Tumour Biol.34(6), 3555–3559 (2013).
   PubMedGoogle Scholar
• Barault L , AmatuA, BleekerFEet al. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann. Oncol. Off.26(9), 1994–1999 (2015).
   PubMed Web of Science ®Google Scholar
• Uno M , Oba-ShinjoSM, CamargoAAet al. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (Sao Paulo)66(10), 1747–1755 (2011).
   PubMed Web of Science ®Google Scholar
• Motomura K , NatsumeA, KishidaYet al. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer117(8), 1721–1730 (2011).
   PubMed Web of Science ®Google Scholar
• Kitange GJ , CarlsonBL, MladekACet al. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J. Neurooncol.92(1), 23–31 (2009).
   PubMed Web of Science ®Google Scholar
• Quillien V , LavenuA, SansonMet al. Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J. Neurooncol.116(3), 487–496 (2014).
   PubMed Web of Science ®Google Scholar
• Reifenberger G , HentschelB, FelsbergJet al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int. J. Cancer131(6), 1342–1350 (2012).
   PubMed Web of Science ®Google Scholar
• Felsberg J , ThonN, EigenbrodSet al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int. J. Cancer129(3), 659–670 (2011).
   PubMed Web of Science ®Google Scholar
• Gerstner ER , YipS, WangDL, LouisDN, IafrateAJ, BatchelorTT. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology73(18), 1509–1510 (2009).
   PubMed Web of Science ®Google Scholar